Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.

@article{Ohara2012CombinedAO,
  title={Combined administration of quinidine and propafenone for atrial fibrillation: the CAQ-PAF study.},
  author={Gilles O'hara and François Philippon and Marcel Gilbert and Jean Champagne and V{\'e}ronique Michaud and Lyne Charbonneau and Guylaine Pruneau and Bettina A Hamelin and P. J. M. Geelen and J. Martin Turgeon},
  journal={Journal of clinical pharmacology},
  year={2012},
  volume={52 2},
  pages={171-9}
}
Propafenone and its 5-hydroxy metabolite exhibit different electrophysiological properties. Objectives of the CAQ-PAF study were (1) to develop a strategy favoring propafenone instead of 5-hydroxypropafenone in plasma following oral administration of propafenone and (2) to evaluate the potential of low-dose quinidine to chronically inhibit CYP2D6. Patients (n = 102) with atrial fibrillation received propafenone 150 mg 3 times daily with either quinidine 100 mg twice daily or placebo. Throughout… CONTINUE READING